

# Michael Farrell

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/961207/publications.pdf>

Version: 2024-02-01

270  
papers

17,719  
citations

15001

68  
h-index

18944

123  
g-index

281  
all docs

281  
docs citations

281  
times ranked

17282  
citing authors

#	ARTICLE	IF	CITATIONS
1	Characteristics of fatal gabapentinoid-related poisoning in Australia, 2000–2020. <i>Clinical Toxicology</i> , 2022, 60, 304-310.	0.8	5
2	Economic analysis of out-of-pocket costs among people in opioid agonist treatment: A cross-sectional survey in three Australian jurisdictions. <i>International Journal of Drug Policy</i> , 2022, 99, 103472.	1.6	11
3	Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence. <i>International Journal of Drug Policy</i> , 2022, 100, 103492.	1.6	22
4	Modeling the population-level impact of opioid agonist treatment on mortality among people accessing treatment between 2001 and 2020 in New South Wales, Australia. <i>Addiction</i> , 2022, 117, 1338-1352.	1.7	11
5	Trends in comorbid opioid and stimulant use disorders among Veterans receiving care from the Veterans Health Administration, 2005–2019. <i>Drug and Alcohol Dependence</i> , 2022, 232, 109310.	1.6	11
6	Examining the cost and impact of dosing fees among clients in opioid agonist treatment: Results from a cross-sectional survey of Australian treatment clients. <i>Drug and Alcohol Review</i> , 2022, 41, 841-850.	1.1	7
7	Characteristics of fatal tapentadol-related toxicity in Australia. <i>Drug and Alcohol Review</i> , 2022, , .	1.1	2
8	The impact of opioid agonist treatment on hospitalisations for injecting-related diseases among an opioid dependent population: A retrospective data linkage study. <i>Drug and Alcohol Dependence</i> , 2022, 236, 109494.	1.6	12
9	Can a new formulation of opiate agonist treatment alter stigma?: Place, time and things in the experience of extended-release buprenorphine depot. <i>International Journal of Drug Policy</i> , 2022, 107, 103788.	1.6	18
10	Characteristics and circumstances of death related to the self-administration of ketamine. <i>Addiction</i> , 2021, 116, 339-345.	1.7	9
11	When the evidence is not enough: is it time to rethink trial design?. <i>Addiction</i> , 2021, 116, 711-712.	1.7	1
12	Assessing the concurrent validity, inter-rater reliability and test-retest reliability of the Australian Treatment Outcomes Profile (ATOP) in alcohol and opioid treatment populations. <i>Addiction</i> , 2021, 116, 1245-1255.	1.7	9
13	Trajectories of alcohol-induced blackouts in adolescence: early risk factors and alcohol use disorder outcomes in early adulthood. <i>Addiction</i> , 2021, 116, 2039-2048.	1.7	8
14	Trends in cocaine use, markets and harms in Australia, 2003–2019. <i>Drug and Alcohol Review</i> , 2021, 40, 946-956.	1.1	15
15	Retention of opioid agonist treatment prescribers across New South Wales, Australia, 2001–2018: Implications for treatment systems and potential impact on client outcomes. <i>Drug and Alcohol Dependence</i> , 2021, 219, 108464.	1.6	10
16	Pharmaceutical Opioid Use Patterns and Indicators of Extramedical Use and Harm in Adults With Chronic Noncancer Pain, 2012-2018. <i>JAMA Network Open</i> , 2021, 4, e213059.	2.8	4
17	Determining clinical cutoff scores for the Australian Treatment Outcomes Profile psychological health, physical health and quality of life questions. <i>Drug and Alcohol Review</i> , 2021, , .	1.1	4
18	Effect of Cytisine vs Varenicline on Smoking Cessation. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 56.	3.8	50

#	ARTICLE	IF	CITATIONS
19	Who would try (or use more) cannabis if it were legal?. Drug and Alcohol Review, 2021, , .	1.1	3
20	What can we learn from the history of research on psychedelic drugs in the addictions?. Addiction, 2021, 116, 2936-2938.	1.7	2
21	Patterns of smoking and injecting methamphetamine and their association with health and social outcomes. Drug and Alcohol Review, 2021, 40, 1256-1265.	1.1	10
22	Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence. JAMA Psychiatry, 2021, 78, 979.	6.0	244
23	Clinical correlates and outcomes associated with pregabalin use among people prescribed opioids for chronic non-cancer pain: A five-year prospective cohort study. British Journal of Clinical Pharmacology, 2021, 87, 3092-3104.	1.1	9
24	Perceptions of injectable opioid agonist treatment (iOAT) among people who regularly use opioids in Australia: findings from a cross-sectional study in three Australian cities. Addiction, 2021, 116, 1482-1494.	1.7	3
25	Fatal opioid overdoses during and shortly after hospital admissions in England: A case-crossover study. PLoS Medicine, 2021, 18, e1003759.	3.9	23
26	Aldous Huxley's Doors of Perception. Addiction, 2021, , .	1.7	1
27	Development of a Brief Patient-Administered Screening Tool for Prescription Opioid Dependence for Primary Care Settings. Pain Medicine, 2020, 21, e79-e88.	0.9	8
28	Effect of increasing the delivery of smoking cessation care in alcohol and other drug treatment centres: a cluster-randomized controlled trial. Addiction, 2020, 115, 1345-1355.	1.7	9
29	Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia. Addiction, 2020, 115, 1295-1305.	1.7	46
30	Risk factors for indicators of opioid-related harms amongst people living with chronic non-cancer pain: Findings from a 5-year prospective cohort study. EClinicalMedicine, 2020, 28, 100592.	3.2	16
31	Integrating HIV pre-exposure prophylaxis and harm reduction among men who have sex with men and transgender women to address intersecting harms associated with stimulant use: a modelling study. Journal of the International AIDS Society, 2020, 23, e25495.	1.2	14
32	The contribution of methamphetamine use to crime: Evidence from Australian longitudinal data. Drug and Alcohol Dependence, 2020, 216, 108262.	1.6	15
33	Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study. BMJ Open, 2020, 10, e034389.	0.8	9
34	The Lower-Risk Cannabis Use Guidelines (LRCUG): A ready-made targeted prevention tool for cannabis in New Zealand. Public Health in Practice, 2020, 1, 100046.	0.7	1
35	Prevalence and Characteristics Associated with Chronic Noncancer Pain in Suicide Decedents: A National Study. Suicide and Life-Threatening Behavior, 2020, 50, 778-791.	0.9	11
36	Pain and dyskinesia in Parkinson's disease may share common pathophysiological mechanisms - An fMRI study. Journal of the Neurological Sciences, 2020, 416, 116905.	0.3	6

#	ARTICLE	IF	CITATIONS
37	Commentary on Hoet al. (2020): Managing people with HIV and drug problems is complex and multi-faceted. <i>Addiction</i> , 2020, 115, 653-654.	1.7	0
38	Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. <i>Addiction</i> , 2019, 114, 150-166.	1.7	178
39	Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. <i>Molecular Psychiatry</i> , 2019, 24, 1868-1883.	4.1	215
40	Post-marketing studies of pharmaceutical opioid abuse-deterrent formulations: a framework for research design and reporting. <i>Addiction</i> , 2019, 114, 389-399.	1.7	11
41	Circumstances of death of opioid users being treated with naltrexone. <i>Addiction</i> , 2019, 114, 2000-2007.	1.7	6
42	Responding to global stimulant use: challenges and opportunities. <i>Lancet, The</i> , 2019, 394, 1652-1667.	6.3	169
43	Strategies to reduce drug-related harm: responding to the evidence base. <i>Lancet, The</i> , 2019, 394, 1490-1493.	6.3	15
44	Mental health outcomes associated with the use of amphetamines: A systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2019, 16, 81-97.	3.2	91
45	Characteristics and circumstances of death related to new psychoactive stimulants and hallucinogens in Australia. <i>Drug and Alcohol Dependence</i> , 2019, 204, 107556.	1.6	19
46	Mortality among people with regular or problematic use of amphetamines: a systematic review and meta-analysis. <i>Addiction</i> , 2019, 114, 1738-1750.	1.7	32
47	Effectiveness and framing of pharmaceutical opioid abuse-deterrent formulations. <i>Addiction</i> , 2019, 114, 404-405.	1.7	2
48	Antidepressant Use Among People Prescribed Opioids for Chronic Noncancer Pain. <i>Pain Medicine</i> , 2019, 20, 2450-2458.	0.9	12
49	The effectiveness, safety and cost-effectiveness of cytisine versus varenicline for smoking cessation in an Australian population: a study protocol for a randomized controlled non-inferiority trial. <i>Addiction</i> , 2019, 114, 923-933.	1.7	11
50	Factors associated with Quitline and pharmacotherapy utilisation among low-socioeconomic status smokers. <i>Addictive Behaviors</i> , 2019, 89, 113-120.	1.7	7
51	Commentary on McDonald <i>et al</i> . (2018): Intranasal naloxone "from the laboratory to the real world. <i>Addiction</i> , 2018, 113, 494-495.	1.7	0
52	Pain sensitivity in Parkinson's disease: Systematic review and meta-analysis. <i>Parkinsonism and Related Disorders</i> , 2018, 48, 17-27.	1.1	30
53	The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study. <i>Lancet Psychiatry</i> , 2018, 5, 155-166.	3.7	28
54	The minimal number of TMS trials required for the reliable assessment of corticospinal excitability, short interval intracortical inhibition, and intracortical facilitation. <i>Neuroscience Letters</i> , 2018, 674, 94-100.	1.0	62

#	ARTICLE	IF	CITATIONS
55	Crossover design in transcranial direct current stimulation studies on motor learning: potential pitfalls and difficulties in interpretation of findings. <i>Reviews in the Neurosciences</i> , 2018, 29, 463-473.	1.4	10
56	Parkinson disease: A systemic review of pain sensitivities and its association with clinical pain and response to dopaminergic stimulation. <i>Journal of the Neurological Sciences</i> , 2018, 395, 172-206.	0.3	20
57	Cannabis use and non-cancer chronic pain – Authors' reply. <i>Lancet Public Health</i> , The, 2018, 3, e469.	4.7	1
58	Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. <i>Pain</i> , 2018, 159, 1932-1954.	2.0	321
59	Prisoners and risk of injury after release. <i>Lancet Public Health</i> , The, 2018, 3, e209-e210.	4.7	1
60	Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. <i>Lancet Public Health</i> , The, 2018, 3, e341-e350.	4.7	172
61	Burroughsâ€™ – Letter from a master addict to dangerous drugsâ€™: a forgotten classic. <i>Addiction</i> , 2018, 113, 2305-2308.	1.7	0
62	Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. <i>Addiction</i> , 2018, 113, 1905-1926.	1.7	685
63	Crystalline methamphetamine use and methamphetamine-related harms in Australia. <i>Drug and Alcohol Review</i> , 2017, 36, 160-170.	1.1	126
64	Does exposure to opioid substitution treatment in prison reduce the risk of death after release? A national prospective observational study in England. <i>Addiction</i> , 2017, 112, 1408-1418.	1.7	130
65	Drinking-reduction goals offer potential to widen the options for measuring and treating alcohol dependence. <i>Lancet Psychiatry</i> , the, 2017, 4, 430-431.	3.7	5
66	Excessive gambling and gaming: addictive disorders?. <i>Lancet Psychiatry</i> , the, 2017, 4, 433-435.	3.7	9
67	Yes, people can die from opiate withdrawal. <i>Addiction</i> , 2017, 112, 199-200.	1.7	26
68	Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis. <i>Neuropsychopharmacology</i> , 2017, 42, 1752-1765.	2.8	190
69	Trends in new psychoactive substances from surface and –dark–net monitoring. <i>Lancet Psychiatry</i> , the, 2017, 4, 16-18.	3.7	15
70	Stroke and methamphetamine use in young adults: a review. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 1079-1091.	0.9	103
71	Predictors of retention in a randomised trial of smoking cessation in low-socioeconomic status Australian smokers. <i>Addictive Behaviors</i> , 2017, 64, 13-20.	1.7	22
72	Smoking and finances: baseline characteristics of low income daily smokers in the FISCALS cohort. <i>International Journal for Equity in Health</i> , 2017, 16, 157.	1.5	4

#	ARTICLE	IF	CITATIONS
73	An organisational change intervention for increasing the delivery of smoking cessation support in addiction treatment centres: study protocol for a randomized controlled trial. <i>Trials</i> , 2016, 17, 290.	0.7	10
74	Defining problematic pharmaceutical opioid use among people prescribed opioids for chronic noncancer pain: do different measures identify the same patients?. <i>Pain</i> , 2016, 157, 1489-1498.	2.0	43
75	Coping with problematic drug use in the family: An evaluation of the <sc>Stepping</sc>stones program. <i>Drug and Alcohol Review</i> , 2016, 35, 470-476.	1.1	10
76	Alpha<sub>2</sub>-adrenergic agonists for the management of opioid withdrawal. <i>The Cochrane Library</i> , 2016, 2016, CD002024.	1.5	122
77	â€˜The lesser of two evilsâ€™™: A qualitative study of staff and client experiences and beliefs about addressing tobacco in addiction treatment settings. <i>Drug and Alcohol Review</i> , 2016, 35, 92-101.	1.1	20
78	Response to commentaries on â€˜Which medications are suitable for agonist drug maintenanceâ€™™. <i>Addiction</i> , 2016, 111, 781-782.	1.7	1
79	Commentary on Singh <i>et al</i>. (2016): Still searching for the answer. <i>Addiction</i> , 2016, 111, 1347-1347.	1.7	2
80	Which medications are suitable for agonist drug maintenance?. <i>Addiction</i> , 2016, 111, 767-774.	1.7	28
81	Prevalence and Correlates of Suicidal Thoughts and Suicide Attempts in People Prescribed Pharmaceutical Opioids for Chronic Pain. <i>Clinical Journal of Pain</i> , 2016, 32, 292-301.	0.8	39
82	A systematic review of modelling approaches in economic evaluations of health interventions for drug and alcohol problems. <i>BMC Health Services Research</i> , 2016, 16, 127.	0.9	22
83	Commentary on Binswanger <i>et al</i>. (2016): Multiple opportunities exist to improve the health and wellbeing of people released from prisons. <i>Addiction</i> , 2016, 111, 511-512.	1.7	0
84	Swift and certain approaches to reduce alcohol reoffending. <i>Lancet Psychiatry</i> , 2016, 3, 189-190.	3.7	0
85	Griffith Edwards, the Addiction Research Unit and research on the criminal justice system. <i>Addiction</i> , 2015, 110, 54-58.	1.7	0
86	The use of paracetamol (acetaminophen) among a community sample of people with chronic non-cancer pain prescribed opioids. <i>International Journal of Clinical Practice</i> , 2015, 69, 1366-1376.	0.8	7
87	<i>Demons: Our Changing Attitudes to Alcohol, Tobacco, and Drugs</i> edited by Virginia Berridge (Ed) Oxford, UK: Oxford University Press, 2013 ISBN: 9780190604982, 292 pp. Hardback. Price: £16.99. <i>Drug and Alcohol Review</i> , 2015, 34, 231-231.		
88	Experience of adjunctive cannabis use for chronic non-cancer pain: Findings from the Pain and Opioids IN Treatment (POINT) study. <i>Drug and Alcohol Dependence</i> , 2015, 147, 144-150.	1.6	97
89	Variation in mortality risk of people released from prison. <i>Lancet Psychiatry</i> , 2015, 2, 681.	3.7	3
90	The introduction of a potentially abuse deterrent oxycodone formulation: Early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study. <i>Drug and Alcohol Dependence</i> , 2015, 151, 56-67.	1.6	29

#	ARTICLE	IF	CITATIONS
91	Factors associated with the development of depression in chronic non-cancer pain patients following the onset of opioid treatment for pain. <i>Journal of Affective Disorders</i> , 2015, 184, 72-80.	2.0	30
92	Heroin-assisted treatment: has a controversial treatment come of age?. <i>British Journal of Psychiatry</i> , 2015, 207, 3-4.	1.7	15
93	Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol. <i>Addiction</i> , 2015, 110, 226-237.	1.7	19
94	The role of Cochrane reviews in informing international guidelines: a case study of using the Grading of Recommendations Assessment, Development and Evaluation system to develop World Health Organization guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. <i>Addiction</i> , 2015, 110, 891-898.	1.7	147
95	Excess mortality among opioid-using patients treated with oral naltrexone in Australia. <i>Drug and Alcohol Review</i> , 2015, 34, 90-96.	1.1	18
96	Reducing extramedical use and harms of pharmaceutical opioids: the potential role of abuse-deterrent formulations. <i>Lancet Psychiatry</i> , 2015, 2, 957-959.	3.7	3
97	The effectiveness and cost-effectiveness of diversion and aftercare programmes for offenders using class A drugs: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2015, 19, 1-168.	1.3	28
98	Drug legalisation. <i>BMJ</i> , 2014, 349, g5233-g5233.	3.0	2
99	Should doctors prescribe cannabinoids?. <i>BMJ</i> , 2014, 348, g2737-g2737.	3.0	15
100	Opioid substitution therapy as a strategy to reduce deaths in prison: retrospective cohort study. <i>BMJ Open</i> , 2014, 4, e004666.	0.8	54
101	A randomized clinical trial of a financial education intervention with nicotine replacement therapy (NRT) for low socioeconomic status Australian smokers: a study protocol. <i>Addiction</i> , 2014, 109, 1602-1611.	1.7	13
102	Would legalizing illicit opioids reduce overdose fatalities? Implications from a natural experiment. <i>Addiction</i> , 2014, 109, 1237-1242.	1.7	21
103	Compulsory treatment of addiction in the patient's best interests: More rigorous evaluations are essential. <i>Drug and Alcohol Review</i> , 2014, 33, 268-271.	1.1	15
104	The impact of opioid substitution therapy on mortality post-release from prison: retrospective data linkage study. <i>Addiction</i> , 2014, 109, 1306-1317.	1.7	165
105	Estimated verbal IQ and the odds of problem gambling: a population-based study. <i>Psychological Medicine</i> , 2014, 44, 1739-1749.	2.7	15
106	The closure of the Silk Road: what has this meant for online drug trading?. <i>Addiction</i> , 2014, 109, 517-518.	1.7	38
107	Alpha <sub>2</sub> -adrenergic agonists for the management of opioid withdrawal. , 2014, , CD002024.		44
108	A systematic review and meta-analysis of naltrexone implants for the treatment of opioid dependence. <i>Drug and Alcohol Review</i> , 2014, 33, 115-128.	1.1	41

#	ARTICLE	IF	CITATIONS
109	Cohort protocol paper: The Pain and Opioids In Treatment (POINT) study. BMC Pharmacology & Toxicology, 2014, 15, 17.	1.0	39
110	Psychosocial treatment for opiate abuse and dependence. The Cochrane Library, 2014, , CD004330.	1.5	5
111	The relationship between personal debt and specific common mental disorders. European Journal of Public Health, 2013, 23, 108-113.	0.1	113
112	Trends in fentanyl prescriptions and fentanyl-related mortality in Australia. Drug and Alcohol Review, 2013, 32, 269-275.	1.1	60
113	Job Strain, Hazardous Drinking, and Alcohol-Related Disorders Among Brazilian Bank Workers. Journal of Studies on Alcohol and Drugs, 2013, 74, 212-222.	0.6	10
114	Commentary on Kelly & Hulse (2012): Is the comparison of mortality between patients prescribed implanted or oral naltrexone an unbiased and unconfounded comparison?. Addiction, 2012, 107, 1825-1826.	1.7	2
115	Maintenance drugs to treat opioid dependence. BMJ, The, 2012, 344, e2823-e2823.	3.0	18
116	The effectiveness of opioid maintenance treatment in prison settings: a systematic review. Addiction, 2012, 107, 501-517.	1.7	215
117	Opioid maintenance in European prisons: is the treatment gap closing?. Addiction, 2012, 107, 461-463.	1.7	15
118	Cochrane systematic reviews in the field of addiction: What's there and what should be. Drug and Alcohol Dependence, 2011, 113, 96-103.	1.6	26
119	Patterns of polydrug use in Great Britain: Findings from a national household population survey. Drug and Alcohol Dependence, 2011, 113, 222-228.	1.6	114
120	Minimising the misuse of oxycodone and other pharmaceutical opioids in Australia. Medical Journal of Australia, 2011, 195, 248-249.	0.8	21
121	Commentary on Agrawal et al. (2011): Assessing the impact of changes to diagnostic criteria on the estimated prevalence of alcohol use disorders in general population surveys. Addiction, 2011, 106, 1944-1945.	1.7	1
122	Happiness across age groups: results from the 2007 National Psychiatric Morbidity Survey. International Journal of Geriatric Psychiatry, 2011, 26, 608-614.	1.3	37
123	The treatment of common mental disorders across age groups: Results from the 2007 adult psychiatric morbidity survey. Journal of Affective Disorders, 2010, 127, 96-101.	2.0	48
124	Hepatitis B vaccination in prisons: a much-needed targeted universal intervention. Addiction, 2010, 105, 189-190.	1.7	10
125	CLASSIFICATION AND CONFUSION. Addiction, 2010, 105, 1150-1150.	1.7	4
126	Meta-analysis of drug-related deaths soon after release from prison. Addiction, 2010, 105, 1545-1554.	1.7	518



#	ARTICLE	IF	CITATIONS
127	Community treatments for heroin and crack cocaine addiction – Authors' reply. <i>Lancet, The</i> , 2010, 375, 278-279.	6.3	1
128	Borderline personality disorder: health service use and social functioning among a national household population. <i>Psychological Medicine</i> , 2009, 39, 1721.	2.7	72
129	Psychopathy among prisoners in England and Wales. <i>International Journal of Law and Psychiatry</i> , 2009, 32, 134-141.	0.5	140
130	The comorbidity of personality disorder and clinical syndromes in prisoners. <i>Criminal Behaviour and Mental Health</i> , 2009, 19, 321-333.	0.4	36
131	The British Mental Health Survey Programme: achievements and latest findings. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2009, 44, 899-904.	1.6	78
132	Is socioeconomic status in early life associated with drug use? A systematic review of the evidence. <i>Drug and Alcohol Review</i> , 2009, 28, 142-153.	1.1	110
133	Alpha2-adrenergic agonists for the management of opioid withdrawal. , 2009, , CD002024.		39
134	Effectiveness of community treatments for heroin and crack cocaine addiction in England: a prospective, in-treatment cohort study. <i>Lancet, The</i> , 2009, 374, 1262-1270.	6.3	103
135	Motivational Interviewing in the Treatment of Psychological Problems Edited by Hal Arkowitz, Henny A. Westra, William R. Miller & Stephen Rollnick. Guilford. 2007. US\$38.00 (hb). 354pp. ISBN: 9781593855857. <i>British Journal of Psychiatry</i> , 2009, 194, 471-471.	1.7	1
136	Acute risk of drug-related death among newly released prisoners in England and Wales. <i>Addiction</i> , 2008, 103, 251-255.	1.7	255
137	Validation of the alcohol, smoking and substance involvement screening test (ASSIST). <i>Addiction</i> , 2008, 103, 1039-1047.	1.7	825
138	Development of the treatment outcomes profile. <i>Addiction</i> , 2008, 103, 1450-1460.	1.7	158
139	Anticonvulsants for cocaine dependence. , 2008, , CD006754.		48
140	Debt, income and mental disorder in the general population. <i>Psychological Medicine</i> , 2008, 38, 1485-1493.	2.7	277
141	Review: Substance use disorders respond to psychosocial interventions. <i>Evidence-Based Mental Health</i> , 2008, 11, 123-123.	2.2	0
142	Depression and common mental disorders in lone parents: results of the 2000 National Psychiatric Morbidity Survey. <i>Psychological Medicine</i> , 2008, 38, 335-342.	2.7	74
143	Alcohol consumption as a risk factor for non-recovery from common mental disorder: results from the longitudinal follow-up of the National Psychiatric Morbidity Survey. <i>Psychological Medicine</i> , 2008, 38, 451-455.	2.7	33
144	Substitution treatment of injecting opioid users for prevention of HIV infection. , 2008, , CD004145.		98

#	ARTICLE	IF	CITATIONS
145	Socioeconomic status in childhood and later alcohol use: a systematic review*. <i>Addiction</i> , 2007, 102, 1546-1563.	1.7	69
146	Substance use and psychiatric comorbidity. <i>Medicine</i> , 2007, 35, 246-249.	0.2	10
147	Substance use and psychiatric comorbidity. <i>Psychiatry (Abingdon, England)</i> , 2007, 6, 23-26.	0.2	1
148	Substance use and psychosis. <i>Psychiatry (Abingdon, England)</i> , 2007, 6, 19-22.	0.2	6
149	Organization and delivery of treatment services for dual diagnosis. <i>Psychiatry (Abingdon, England)</i> , 2007, 6, 34-36.	0.2	9
150	Violence and psychiatric morbidity in the national household population of Britain: public health implications. <i>British Journal of Psychiatry</i> , 2006, 189, 12-19.	1.7	106
151	Trends in cannabis use prior to first presentation with schizophrenia, in South-East London between 1965 and 1999. <i>Psychological Medicine</i> , 2006, 36, 1441-1446.	2.7	63
152	Predictors of mental health service utilization in the 12½ months before imprisonment: analysis of results from a national prisons survey. <i>Australian and New Zealand Journal of Psychiatry</i> , 2006, 40, 548-553.	1.3	2
153	Young People and Substance Misuse. <i>Child and Adolescent Mental Health</i> , 2006, 11, 61-61.	1.8	0
154	An evaluation of a brief motivational intervention among young ecstasy and cocaine users: no effect on substance and alcohol use outcomes. <i>Addiction</i> , 2006, 101, 1014-1026.	1.7	111
155	Obsessive-compulsive disorder and personality disorder. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2006, 41, 862-867.	1.6	53
156	Brief report: Methadone treatment of injecting opioid users for prevention of HIV infection. <i>Journal of General Internal Medicine</i> , 2006, 21, 193-195.	1.3	83
157	Epidemiology of tobacco, alcohol and drug use. <i>Psychiatry (Abingdon, England)</i> , 2006, 5, 427-430.	0.2	1
158	Obsessive-Compulsive Disorder: Prevalence, Comorbidity, Impact, and Help-Seeking in the British National Psychiatric Morbidity Survey of 2000. <i>American Journal of Psychiatry</i> , 2006, 163, 1978-1985.	4.0	281
159	Predictors of Mental Health Service Utilization in the 12 Months before Imprisonment: Analysis of Results from a National Prisons Survey. <i>Australian and New Zealand Journal of Psychiatry</i> , 2006, 40, 548-553.	1.3	13
160	Violence and Psychiatric Morbidity in a National Household Population--A Report from the British Household Survey. <i>American Journal of Epidemiology</i> , 2006, 164, 1199-1208.	1.6	109
161	Brief report: Methadone treatment of injecting opioid users for prevention of HIV infection. <i>Journal of General Internal Medicine</i> , 2006, 21, 193-5.	1.3	66
162	Alcohol consumption as a risk factor for anxiety and depression. <i>British Journal of Psychiatry</i> , 2005, 187, 544-551.	1.7	94

#	ARTICLE	IF	CITATIONS
163	Personal and social correlates of alcohol consumption among mid-adolescents. <i>British Journal of Developmental Psychology</i> , 2005, 23, 427-450.	0.9	29
164	Effectiveness of drug dependence treatment in HIV prevention. <i>International Journal of Drug Policy</i> , 2005, 16, 67-75.	1.6	55
165	CONCURRENT AND CONSTRUCT VALIDITY OF THE AUDIT IN AN URBAN BRAZILIAN SAMPLE. <i>Alcohol and Alcoholism</i> , 2005, 40, 584-589.	0.9	210
166	Psychiatric and social aspects of suicidal behaviour in prisons. <i>Psychological Medicine</i> , 2005, 35, 257-269.	2.7	160
167	Psychosis in the Community and in Prisons: A Report From the British National Survey of Psychiatric Morbidity. <i>American Journal of Psychiatry</i> , 2005, 162, 774-780.	4.0	129
168	Dying for heroin: the increasing opioid-related mortality in the Republic of Ireland, 1980â€“1999. <i>European Journal of Public Health</i> , 2005, 15, 589-592.	0.1	6
169	Trends in service use and treatment for mental disorders in adults throughout Great Britain. <i>British Journal of Psychiatry</i> , 2004, 185, 378-384.	1.7	104
170	Prevalence and correlates of self-reported psychotic symptoms in the British population. <i>British Journal of Psychiatry</i> , 2004, 185, 298-305.	1.7	482
171	HIV in injecting drug users in Asian countries. <i>BMJ: British Medical Journal</i> , 2004, 329, 697-698.	2.4	10
172	Psychosis, victimisation and childhood disadvantage. <i>British Journal of Psychiatry</i> , 2004, 185, 220-226.	1.7	478
173	Substance use and psychosis. <i>Psychiatry (Abingdon, England)</i> , 2004, 3, 52-54.	0.2	5
174	Substance use and psychiatric comorbidity. <i>Psychiatry (Abingdon, England)</i> , 2004, 3, 55-58.	0.2	3
175	Organization and delivery of treatment services for dual diagnosis. <i>Psychiatry (Abingdon, England)</i> , 2004, 3, 62-64.	0.2	2
176	Risk factors and the prevalence of neurosis and psychosis in ethnic groups in Great Britain. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2004, 39, 939-946.	1.6	45
177	Psychosocial treatment for opiate abuse and dependence. , 2004, , CD004330.		53
178	Alpha2 adrenergic agonists for the management of opioid withdrawal. , 2004, , CD002024.		18
179	Drug-Related Mortality and Fatal Overdose Risk: Pilot Cohort Study of Heroin Users Recruited From Specialist Drug Treatment Sites in London. <i>Journal of Urban Health</i> , 2003, 80, 274-287.	1.8	87
180	The reluctance to seek treatment for neurotic disorders. <i>International Review of Psychiatry</i> , 2003, 15, 123-128.	1.4	74

#	ARTICLE	IF	CITATIONS
181	Minimizing respondent attrition in longitudinal research: Practical implications from a cohort study of adolescent drinking. <i>Journal of Adolescence</i> , 2003, 26, 363-373.	1.2	99
182	Substance misuse among prisoners in England and Wales. <i>International Review of Psychiatry</i> , 2003, 15, 150-152.	1.4	53
183	British Psychiatric Morbidity Survey. <i>International Review of Psychiatry</i> , 2003, 15, 14-18.	1.4	14
184	The influence of age and sex on the prevalence of depressive conditions: report from the National Survey of Psychiatric Morbidity. <i>International Review of Psychiatry</i> , 2003, 15, 74-83.	1.4	132
185	Socio-economic status, standard of living, and neurotic disorder. <i>International Review of Psychiatry</i> , 2003, 15, 91-96.	1.4	36
186	Substance misuse and psychiatric comorbidity: an overview of the OPCS National Psychiatric Morbidity Survey. <i>International Review of Psychiatry</i> , 2003, 15, 43-49.	1.4	29
187	Unequal access and unmet need: neurotic disorders and the use of primary care services. <i>International Review of Psychiatry</i> , 2003, 15, 115-122.	1.4	26
188	Nicotine, alcohol and drug dependence, and psychiatric comorbidity--results of a national household survey. <i>International Review of Psychiatry</i> , 2003, 15, 50-56.	1.4	56
189	Psychiatric morbidity in prisoners and solitary cellular confinement, II: special ('strip') cells. <i>Journal of Forensic Psychiatry and Psychology</i> , 2003, 14, 320-340.	0.6	15
190	Neurotic disorders and the receipt of psychiatric treatment. <i>International Review of Psychiatry</i> , 2003, 15, 108-114.	1.4	25
191	Psychiatric morbidity in prisoners and solitary cellular confinement, I: disciplinary segregation. <i>Journal of Forensic Psychiatry and Psychology</i> , 2003, 14, 298-319.	0.6	31
192	The National Psychiatric Morbidity Surveys of Great Britain--strategy and methods. <i>International Review of Psychiatry</i> , 2003, 15, 5-13.	1.4	13
193	The National Psychiatric Morbidity Surveys of Great Britain--initial findings from the Household Survey. <i>International Review of Psychiatry</i> , 2003, 15, 29-42.	1.4	60
194	Social support networks and type of neurotic symptom among adults in British households. <i>Psychological Medicine</i> , 2003, 33, 307-318.	2.7	50
195	Lone mothers, social exclusion and depression. <i>Psychological Medicine</i> , 2003, 33, 715-722.	2.7	97
196	Psychiatric morbidity and substance use in young people aged 13-15 years: results from the Child and Adolescent Survey of Mental Health. <i>British Journal of Psychiatry</i> , 2003, 182, 509-517.	1.7	111
197	Psychosis and drug dependence: results from a national survey of prisoners. <i>British Journal of Psychiatry</i> , 2002, 181, 393-398.	1.7	120
198	The National Survey of Psychiatric Morbidity among Prisoners and the Future of Prison Healthcare. <i>Medicine, Science and the Law</i> , 2002, 42, 245-250.	0.6	22

#	ARTICLE	IF	CITATIONS
199	Prison based detoxification for opioid dependence: a randomised double blind controlled trial of lofexidine and methadone. <i>Drug and Alcohol Dependence</i> , 2002, 67, 169-176.	1.6	53
200	Ethnic differences in prisoners. <i>British Journal of Psychiatry</i> , 2002, 181, 481-487.	1.7	36
201	Ethnic differences in prisoners. <i>British Journal of Psychiatry</i> , 2002, 181, 473-480.	1.7	43
202	Reducing Drug Related Deaths By The Advisory Council on the Misuse of Drugs. London: Stationery Office. 2000. 123 pp. £11.50. ISBN: 0-11-341-239-8.. <i>Psychiatric Bulletin</i> , 2002, 26, 119-119.	0.3	17
203	± 2 -Adrenergic agonists in opioid withdrawal. <i>Addiction</i> , 2002, 97, 49-58.	1.7	63
204	The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility. <i>Addiction</i> , 2002, 97, 1183-1194.	1.7	1,344
205	Methamphetamine: drug use and psychoses becomes a major public health issue in the Asia Pacific region. <i>Addiction</i> , 2002, 97, 771-772.	1.7	101
206	Pharmacological treatment of cocaine dependence: a systematic review. <i>Addiction</i> , 2002, 97, 931-949.	1.7	149
207	Drug use and initiation in prison: results from a national prison survey in England and Wales. <i>Addiction</i> , 2002, 97, 1551-1560.	1.7	131
208	The relative impact of waiting time and treatment entry on drug and alcohol use. <i>Addiction Biology</i> , 2002, 7, 67-74.	1.4	26
209	Drugs: Dilemmas and Choices By a Working Party of the Royal College of Psychiatrists and the Royal College of Physicians. London: Gaskell. 2000. 304 pp. £9.50 (pb). ISBN 1 901242 447. <i>British Journal of Psychiatry</i> , 2001, 178, 484-484.	1.7	12
210	Cannabis and health. <i>British Journal of Psychiatry</i> , 2001, 178, 98-98.	1.7	8
211	Nicotine, alcohol and drug dependence and psychiatric comorbidity. <i>British Journal of Psychiatry</i> , 2001, 179, 432-437.	1.7	250
212	Psychiatric symptoms among clients seeking treatment for drug dependence. <i>British Journal of Psychiatry</i> , 2000, 176, 285-289.	1.7	151
213	Unequal access and unmet need: neurotic disorders and the use of primary care services. <i>Psychological Medicine</i> , 2000, 30, 1359-1367.	2.7	200
214	Neurotic disorders and the receipt of psychiatric treatment. <i>Psychological Medicine</i> , 2000, 30, 1369-1376.	2.7	140
215	Randomized trial of supervised injectable versus oral methadone maintenance: report of feasibility and 6-month outcome. <i>Addiction</i> , 2000, 95, 1631-1645.	1.7	56
216	Use of non-prescribed methadone and other illicit drugs during methadone maintenance treatment. <i>Drug and Alcohol Review</i> , 2000, 19, 9-16.	1.1	38

#	ARTICLE	IF	CITATIONS
217	Client Perceptions of Inpatient Treatment: a qualitative account with implications for service delivery. <i>Drugs: Education, Prevention and Policy</i> , 1999, 6, 87-97.	0.8	14
218	Estimating the prevalence of problem drug use in inner London: a discussion of three capture-recapture studies. <i>Addiction</i> , 1999, 94, 1653-1662.	1.7	54
219	Cannabis dependence and withdrawal. <i>Addiction</i> , 1999, 94, 1277-1278.	1.7	12
220	Benzodiazepines in Polydrug-using Repertoires: the impact of the decreased availability of temazepam gel-filled capsules. <i>Drugs: Education, Prevention and Policy</i> , 1999, 6, 61-69.	0.8	42
221	Route of drug use and its implications for drug effect, risk of dependence and health consequences. <i>Drug and Alcohol Review</i> , 1998, 17, 197-211.	1.1	78
222	The Maudsley Addiction Profile (MAP): a brief instrument for assessing treatment outcome. <i>Addiction</i> , 1998, 93, 1857-1867.	1.7	399
223	Socioeconomic status, standard of living, and neurotic disorder. <i>Lancet, The</i> , 1998, 352, 605-609.	6.3	173
224	Managing anxiety and depression in alcohol and drug dependence. <i>Addictive Behaviors</i> , 1998, 23, 919-931.	1.7	41
225	Substance misuse and psychiatric comorbidity. <i>Addictive Behaviors</i> , 1998, 23, 909-918.	1.7	165
226	Review: family or couples therapy is more effective than non-family therapy for drug abuse. <i>Evidence-Based Mental Health</i> , 1998, 1, 81-81.	2.2	1
227	A programme of methadone maintenance plus moderate counselling services was cost effective. <i>Evidence-Based Mental Health</i> , 1998, 1, 63-63.	2.2	1
228	Cocaine in Britain: Prevalence, Problems, and Treatment Responses. <i>Journal of Drug Issues</i> , 1998, 28, 225-241.	0.6	13
229	The influence of age and sex on the prevalence of depressive conditions: report from the National Survey of Psychiatric Morbidity. <i>Psychological Medicine</i> , 1998, 28, 9-19.	2.7	293
230	Britain's new strategy for tackling drugs misuse. <i>BMJ: British Medical Journal</i> , 1998, 316, 1399-1400.	2.4	11
231	The Swiss heroin trials: testing alternative approaches. <i>BMJ: British Medical Journal</i> , 1998, 316, 639-639.	2.4	45
232	Opioid Substitution: Critical Issues and Future Directions. <i>Journal of Drug Issues</i> , 1998, 28, 243-263.	0.6	10
233	Methadone Treatment for Opiate Addiction: Benefits in the First Month. <i>Addiction Research</i> , 1997, 5, 71-76.	0.6	33
234	The National Psychiatric Morbidity Surveys of Great Britain "initial findings from the Household Survey. <i>Psychological Medicine</i> , 1997, 27, 775-789.	2.7	363

#	ARTICLE	IF	CITATIONS
235	The National Psychiatric Morbidity Surveys of Great Britain " strategy and methods. Psychological Medicine, 1997, 27, 765-774.	2.7	140
236	Comorbidity of mental disorders with substance misuse. British Journal of Psychiatry, 1997, 171, 4-5.	1.7	75
237	Time of day of methadone consumption and illicit heroin use. Drug and Alcohol Dependence, 1997, 49, 49-54.	1.6	10
238	Suicide and substance misuse. British Journal of Psychiatry, 1997, 171, 303-304.	1.7	43
239	Prescription of diamorphine, dipipanone and cocaine in England and Wales. Drug and Alcohol Review, 1997, 16, 221-226.	1.1	15
240	Suicide and overdose among opiate addicts. Addiction, 1996, 91, 321-323.	1.7	50
241	Heroin overdose: the case for take-home naloxone. BMJ: British Medical Journal, 1996, 312, 1435-1436.	2.4	138
242	Directly observed treatment for tuberculosis. BMJ: British Medical Journal, 1996, 313, 45-45.	2.4	5
243	Compressed opiate withdrawal syndrome and naltrexone. Journal of Psychopharmacology, 1995, 9, 383-385.	2.0	9
244	Family Cohesion as a Buffer Against the Effects of Problem-Drinking Fathers on Psychological Distress, Deviant Behavior, and Heavy Drinking in Adolescents. Journal of Health and Social Behavior, 1995, 36, 377.	2.7	79
245	Does prenatal exposure to influenza in mice induce pyramidal cell disarray in the dorsal hippocampus?. Schizophrenia Research, 1995, 16, 233-241.	1.1	46
246	Methadone maintenance treatment. BMJ: British Medical Journal, 1995, 310, 1408-1408.	2.4	2
247	Cocaine: Physiological and Physiopathological Effects. Edited by Alfonso Paredes and David A. Gorelick. New York: Haworth. 1992. 130 pp. US \$26.95 (hb) or \$23.95 (pb).. British Journal of Psychiatry, 1994, 165, 708-709.	1.7	0
248	Methadone-maintenance and the prognosis paradox. Addiction, 1994, 89, 812-813.	1.7	0
249	Opiate withdrawal. Addiction, 1994, 89, 1471-1475.	1.7	117
250	Patients' preferences and randomised trials. Lancet, The, 1994, 344, 688-689.	6.3	8
251	Cocaine: Physiological and Physiopathological Effects. Edited by Alfonso Paredes and David A. Gorelick. New York: Haworth. 1992. 130 pp. US \$26.95 (hb) or \$23.95 (pb).. British Journal of Psychiatry, 1994, 165, 708-709.	1.7	0
252	Substance misusers attending a psychiatric emergency clinic. Journal of Mental Health, 1992, 1, 163-168.	1.0	2

#	ARTICLE	IF	CITATIONS
253	Relapse Prevention for Addictive Behaviours: A Manual for Therapists. By Shamil Wanigaratne, Wendy Wallace, Jane Pullin, Francis Keaney and Roger Farmer. Oxford: Blackwell Scientific Publications. 1990. 205 pp. £12.95.. British Journal of Psychiatry, 1991, 158, 875-875.	1.7	0
254	Substance Use and Misuse in Childhood and Adolescence. Journal of Child Psychology and Psychiatry and Allied Disciplines, 1991, 32, 109-128.	3.1	17
255	Clinical Features of Patients Attending a Gender-Identity Clinic. British Journal of Psychiatry, 1990, 157, 265-268.	1.7	22
256	The lure of masterstrokes: drug legalization. Addiction, 1990, 85, 5-7.	1.7	3
257	Pharmaceutical heroin and 'chasing the dragon' From Malcolm Battersby, Michael Farrell & John Strong. Addiction, 1990, 85, 151-151.	1.7	3
258	Beyond Platitudes: Problem Drug Use: a review of training. Addiction, 1990, 85, 1559-1562.	1.7	8
259	Screening for hepatitis B and vaccination of injecting drug users in NHS drug treatment services. Addiction, 1990, 85, 1657-1659.	1.7	23
260	Discrimination on the grounds of diagnosis. Addiction, 1990, 85, 883-890.	1.7	33
261	Confusion between the drug legalization and the drug prescribing debate. Drug and Alcohol Review, 1990, 9, 364-368.	1.1	2
262	Advanced Summer School in Addictions. Psychiatric Bulletin, 1990, 14, 39-40.	0.3	0
263	New models of services for drug misusers. Psychiatric Bulletin, 1989, 13, 645-647.	0.3	1
264	Ecstasy and the Oxygen of Publicity. Addiction, 1989, 84, 943-943.	1.7	7
265	The Technology of Dragon Chasing. Addiction, 1989, 84, 699-699.	1.7	5
266	Inpatient psychiatric care: The patient's view. The British Journal of Medical Psychology, 1989, 62, 249-255.	0.6	48
267	Young People and Alcohol. Addiction, 1988, 83, 1137-1138.	1.7	0
268	Prescription charges. Bulletin of the Royal College of Psychiatrists, 1987, 11, 102-102.	0.1	0
269	Drug use and drug dependence. , 0, , 230-249.		1
270	Opioid agonist maintenance for opioid dependent patients in prison. The Cochrane Library, 0, , .	1.5	0